• Biobehavioral Imaging &

    Molecular Neuropsychopharmacology


    at the National Institute on Drug Abuse/NIH

    Intramural Research Program

  • Who we are

    We are a group of scientists working to understand the brain and its involvement in disease with a focus on substance use disorders


    We specialize in mechanistic neuropharmacology and development of pharmaceuticals and translational tools for brain mapping and modulation

    I was born in Greece. My family moved to New York when I was 3 years old and then back to Greece when I was 10. As an undergraduate, I attended Stony Brook University (SBU) where I studied Economics and Mathematics. A summer research fellowship in my junior year exposed me to molecular imaging and inspired me to pursue a PhD in Integrative Neuroscience at SBU. My doctoral research was carried out in Dr. Nora Volkow's Laboratory of Neuroimaging. My postdoctoral training was at the Icahn School of Medicine at Mount Sinai in Dr. Yasmin Hurd's Molecular Neuropsychopharmacology laboratory. As of 2015 I am a Tenure-track Investigator at the NIH/NIDA and hold an adjunct Assistant Professor appointment in the Psychiatry & Behavioral Sciences Department at the Johns Hopkins University School of Medicine.

    Juan L. Gomez, Ph.D. - Research Fellow


    A statement about my-[science]-self: I have a curiosity driven by the need to explore; doing my best to improve upon methods and techniques to devise a better way to catch that roadrunner.


    Thoughts on experience: High School - An introduction to the lab, samples, and 96-wells. As a junior, I volunteered my school breaks and weekends to assist a biology graduate collecting and analyzing water/soil samples from rivers in Arizona. I was one of the few high school students among undergraduates to present our findings at the annual Arizona State University poster day. I was hooked. Undergraduate (B.S.) - An undergrad is only an undergrad by name in the lab of Cheryl Conrad at Arizona State University (ASU) where I received a degree in Psychology. These early experiences sharpened my lab work ethic and expectations as a future academic. Graduate (Ph.D.) - Good work with those that work good with you. Mentored by Victoria Luine, we worked with Michael Lewis and others at Hunter College of CUNY (HC) on my dissertation. Collaborations were an integral part of my graduate career, and almost every lab at HC contributed to my development as a scientist, for which I am grateful. Postdoc #1 – Envy has no place in productive endeavors. At my first postdoc in the Behavioral Neuroscience department at Oregon Health & Science University (OHSU), I was exposed to a new level of research and opportunities. Working with Andrey Ryabinin I learned the value of independent research and perseverance during difficult times. Postdoc #2 - Further research is needed… I joined the BIMN lab in 2015. Thus far, the radioactive signal may show me the way.

    Oscar Solís, Ph.D. - IRTA Postdoctoral Fellow


    I was born and raised in the tropical state of Guerrero in Mexico. After high school, I moved to Puebla, where I obtained a BSc in Biochemistry and a MSc degree in Physiology at the Autonomous University of Puebla. During my undergraduate studies, with Dr. Gonzalo Flores at the Physiology Institute, I worked on the alterations of cortical and striatal neurons in a rodent model of Parkinson disease. Then, after being accepted into the Ph.D. program in Neuroscience in Madrid, Spain, I joined the Neurobiology of Basal Ganglia Lab at Cajal Institute. Under the guidance of Prof. Rosario Moratalla, I studied the behavioral and molecular/structural/functional traits relevant to L-DOPA-induced dyskinesia and drug addiction. In my free time, I enjoy playing football, running, traveling and spending time with my family and friends.

    Marjorie Levinstein, Ph.D. - IRTA Postdoctoral Fellow


    I grew up in Virginia where I also earned my bachelor’s in Psychology from James Madison University (2011). However, my first research experience was as a summer internship after my sophomore year on developmental neuroscience at the University of South Carolina. Once back at JMU, I ran several health psychology experiments and volunteered at Western State Hospital. Nevertheless, I realized I was interested in understanding the mechanisms behind behavior and enrolled in a master’s in experimental psychology at Seton Hall University (2013). There, I studied the effect of immune system activity on ethanol consumption. I then joined René Hen’s lab at Columbia University as a research technician. I focused on the pharmacological and biological mechanisms behind several antidepressants. In 2015, I moved across the country to Seattle, Washington where I earned my PhD from the University of Washington in Neuroscience (2020). Mentored under John F. Neumaier, I investigated gene expression changes in the lateral habenula after stress or chemogenetic activation. The east coast called me back, and I moved to Baltimore to join the BIMN lab. Outside of the lab, I enjoy crochet and rooting for the oft-losing Chicago Cubs.

    Emilya Ventriglia B.S., M.S. - IRTA Postbaccalaureate Fellow


    In a Steinbeckian gesture, I moved from my hometown of Oklahoma City, OK to southern California in the pursuit of great opportunity. My passion for neuroscience was fully realized during my studies at the University of California, San Diego. In 2019 I graduated with a B.S. in Physiology & Neuroscience with a minor in music, continued by a M.Sc. in Biology in 2020. Beginning the Spring of my senior year, I began full-time research in the Banghart Lab at UCSD as a continuous BS/MS student, cutting my teeth on behavioral pharmacology and activity-dependent neuroplasticity. I worked primarily with mouse-models for persistent inflammatory pain and opioid-induced hyperalgesia in the vlPAG, the latter being the subject of my thesis. Beyond the bench I enjoy being outdoors, listening to music, and dabbling in different arts.

    Reece Budinich B.S. - IRTA Postbaccalaureate Fellow


    I was born and raised in Federal Way, Washington, a short drive from Seattle. For my undergraduate degree I attended Western Washington University in Bellingham, basically the furthest northwest corner of the beautiful Pacific Northwest. While at WWU, I developed an interest in Psychology. After nearly finishing my degree, I discovered a passion for Behavioral Neuroscience and spent an extra year at university to double major. During this 5th year I joined Dr. Josh Kaplan's Pharmacology of Cannabinoids research lab, where I studied the acute anxiolytic effects of commercial CBD vape products in a mouse model. Throughout my undergraduate degree I found myself in several mentoring positions, both as a Teaching Assistant for multiple classes and an officer in the Neuroscience Research Driven Students Club (NeRDS).

    Outside of academia, I spend my time honing my photography skills and making fancy coffee like a true Seattleite. I love cats, astronomy, and I consume an abysmal amount of cheese.

    Fallon Curry B.S. - IRTA Postbaccalaureate Fellow


    I grew up in Pittsburgh, PA, also referred to as the City of Bridges, or the Steel City, depending on who you ask. Seeking new horizons, I decided to travel down country roads to Virginia Tech. While there, I pursued a B.S. in Neuroscience with minors in Spanish and Public Health. While in school, I wanted to take my education beyond the book, and sought out research opportunities to do so. I joined the lab of Dr. Michelle Olsen during my junior year, where I studied astrocyte development and morphology. Additionally, I had the opportunity to partake in a summer research fellowship before my senior year. I studied under Dr. Shannon Farris, who examines the role of hippocampal area CA2 in encoding social memory. When not in the lab, I love to listen to music, bake, and cheer on the Pittsburgh Penguins.

    Leila Ghaffari - Research Intern


    I grew up in Frederick, Maryland and moved to Baltimore to attend the University of Maryland, Baltimore County (UMBC), and I am currently in my third year. Beginning in high school, I pursued my passion for research and medicine. I interned in the NGHRI of the NIH and shadowed in the Clinical Center. During the Summer after my freshman year, I interned in the Chemical Engineering Department of the University of Virginia, where I understood the impact computers can have on molecular design and peptide synthesis. Throughout this time I am also involved in my sustained research lab on campus studying behavioral neuroscience in drosophila melanogaster under the guidance of Dr. Fernando Vonhoff. Since the fall of 2021, I have been an undergraduate intern in Dr. Michaelides' lab. At UMBC, I am majoring in biological sciences and minoring in computer science and vocal performance. I am interested in behavioral neuroscience and the interdisciplinary studies conducted through biology and computer science. After college I aspire toward a career as a physician scientist. Outside academics I enjoy music, art, and playing with my dog.

  • Research

    Mechanistic Neuropharmacology

    We employ a wide array of complementary in vitro and in vivo pharmacological approaches for dissecting the in vivo mechanism of action of popular CNS medications and recreational drugs.
    Examples of some of the medications we work on are listed below.

    Ketamine & enantiomers

    Ketamine is a controlled substance, has abuse potential, and can induce undesirable side effects. Nevertheless, it is considered to be generally safe and is a widely-used dissociative anesthetic and rapid-acting pain medication. The recent discovery that a single subanesthetic dose of racemic ketamine produces rapid and long-lasting antidepressant effects has been hailed as a key psychiatric breakthrough. (S)-ketamine (esketamine, SpravatoTM) was recently approved by the FDA as an intranasal formulation for treatment-resistant depression and human trials assessing efficacy of (R)-ketamine in depression are currently underway. As depression shares strong comorbidity with substance use disorders, we are working to better understand the precise in vitro and in vivo pharmacological properties and the abuse liability of its enantiomers.

    Bonaventura, et al. 2021

    Bonaventura, et al. 2022

    Bonaventura, et al. 2022

    Levinstein, et al. 2023



    (2R,6R)-hydroxynorketamine (HNK) is a ketamine metabolite implicated in ketamine's efficacy in preclinical models of depression. We are working on the pharmacological characterization of (2R,6R)-HNK, for which human trials are underway.

    Bonaventura, et al. 2022


    Oliceridine (TRV-130)

    Oliceridine is an FDA-approved pain medication. We are working on its in vivo pharmacological characterization and abuse liability profile.

    Ventriglia, et al. 2022


    Methadone & enantiomers

    Racemic methadone is used for treatment of substance abuse. The efficacy of racemic methadone is attributed to (R)-methadone. (S)-methadone is being developed as a treatment for depression. We are working on the pharmacological characterization of (R)-methadone and (S)-methadone as well as their liability for abuse.

    Levinstein, et al. 2023



    Drug Discovery & Development

    We are working on discovery and preclinical development of selective mu opioid receptor agonists for treatment of pain with low abuse liability and adverse effect profiles.


    Figure: Pharmacological screening (% binding or activity inhibition) of a novel selective mu opioid receptor ligand across many receptors and enzymes.

    Molecular imaging & PET radiotracer development

    A large portion of our research program involves the use of molecular imaging via PET. We perform PET studies by employing a variety of radioligands depending on experimental need. These can be procured commercially or are custom made to perform noninvasive, quantitative, and longitudinal assessments of brain metabolic activity, neuroinflammation, neurotransmitter displacement, and receptor occupancy/target engagement of candidate compounds or other processes. We co-implement chemogenetic, optogenetic, pharmacological, ultrasound, or electrical stimulation with PET imaging in awake, freely-moving animals either in an exploratory fashion, to determine whole-brain functional networks recruited during behaviorally-relevant contexts, or to corroborate functional connectivity or target engagement of a defined neuron-type, region, or pathway. We use such approaches to map functional anatomy related to a variety of cell-types/projections in distinct brain regions in basic and translational research.


    Radioligands we currently use:


    [18F]FDG - Glucose analog used for brain metabolic mapping

    [11C]Raclopride - Displaceable dopamine D2/D3 receptor antagonist

    [18F]Fallypride - Displaceable dopamine D2/D3 receptor antagonist

    [18F]FE-DPN - Displaceable mu opioid receptor antagonist

    [18F]FES - Estradiol analog for estrogen receptor and opsin imaging

    [18F]JHU37107 - DREADD agonist

    [11C]clozapine - atypical antipsychotic and DREADD agonist

    [18F]ASEM - Nicotinic alpha7 receptor antagonist and PSAM4 agonist


    Figure: PET image coregistered to MRI showing non-invasive assessment of dopamine D2/D3 receptors using [11C]raclopride in mouse brain.


    We have developed chemogenetic ligands with high affinity and potency that can be used for both in vivo neuromodulation and non-invasive imaging of chemogenetic receptors.

    Figure: Precision medicine offers considerable advantages over conventional medical treatment. Within precision medicine, theranostics comprises a strategy that combines THERApeutic and diagNOSTIC strategies to provide a personalized treatment approach encompassing disease diagnosis, drug delivery, and disease/therapy monitoring using a single agent. Such interventions are particularly timely given recent developments in neuromodulatory technologies. One such technology, called chemogenetics, offers the unprecedented ability to control neuronal activity in a cell type-specific manner without the need for chronically-implantable devices. A key feature of chemogenetic technologies is that they can be combined with clinical molecular imaging diagnostic methods such as positron emission tomography (PET). This particular combination extends the therapeutic component of chemogenetics to encompass its use in precision medicine-based neurotheranostics.


    Gomez, Bonaventura et al. 2017
    Magnus, Lee et al., 2019
    Bonaventura, Eldridge, Hu, et al., 2019
    Hu, Morris Bonaventura, et al., 2020
    Roseboom, et al., 2021
    Song, et al., 2021


    Optogenetics is a widely-used technology consisting of light-activatable ion channels expressed in neural tissue which upon light stimulation can either activate or inhibit neurons with exquisite temporal precision. Optogenetics has had a strong impact on basic neuroscience research. However, its use in translational applications has been limited. One reason for this, is that to date, opsins have not been able to be visualized noninvasively in intact subjects. To address this, we are developing a noninvasive reporter detection system for optogenetics. This scalable system consists of (i) chimeric opsins tagged with a small human protein epitope and (ii) an FDA-approved PET radioligand and permits both optogenetic neuromodulation and noninvasive, quantitative, and longitudinal detection of opsins in the brain.

    Figure: A novel chimeric opsin called ChRERa (pronounced "carrera") that consists of Channelrhodopsin-2 and the ligand binding domain (LBD) of human estrogen receptor alpha (ERa).


    Bonaventura, Boehm et al. (under review)


    For more details our "Hot Topics" presentation at the ACNP 2019 meeting can be found here
    Synchrotron X-Ray Fluorescence Microscopy of Zn (red) , Fe (green) and Cu (blue) in the rodent striatum

    Synaptic Zinc

    Synaptic zinc is transported into synaptic vesicles via the ZnT3 (Slc30a3) transporter and is co-released from presynaptic terminals along with glutamate. Synaptic zinc is essential for normal neurobiological functioning. Studies have shown that people with substance and alcohol use disorders have abnormal zinc levels. Nevertheless, the precise involvement of synaptic zinc in normal neurobiology, and in substance and alcohol use disorders are not well understood. The dopamine transporter is the principal target for cocaine and contains four zinc binding sites on its extracellular domain. We recently showed that synaptic zinc potentiates the effects of cocaine on dopamine neurotransmission and behavior. We are currently working to better understand the role of synaptic zinc in modulating neurochemistry and behavior and the extent to which this is relevant to substance and alcohol use disorders.


    Ongoing efforts involve development of a ZnT3-cre mouse, dissecting the role of ZnT3-expressing neurons in behaviors relevant to substance use disorder, and development of ZnT3-selective small molecules.

    Figure: (Top) At physiological concentrations, zinc increases the binding of the cocaine analog [3H]WIN35,428 as well as of cocaine itself at the dopamine transporter. (Bottom) [3H]WIN35,428 autoradiography in a coronal mouse brain section showing that zinc increases binding of [3H]WIN35,428 in the striatum.

  • Publications

    Interactions of Calmodulinkinase II with the Dopamine Transporter Facilitate Cocaine-induced Enhancement
    of Evoked Dopamine Release


    Relevance of the Viral Spike Protein/Cellular Estrogen Receptor-α Interaction for Endothelial-based Coagulopathy Induced by SARS-CoV-2


    A CRE/DRE Dual Recombinase Transgenic Mouse Reveals Synaptic Zinc-mediated Thalamocortical Neuromodulation


    Effect of Selective Lesions of Nucleus Accumbens μ-Opioid Receptor-Expressing Cells on Heroin Self-Administration in Male and Female Rats: a Study with Novel Oprm1-Cre Knock-in Rats


    Mu Opioid Receptor Activation Mediates (S)-ketamine Reinforcement in Rats: Implications for Abuse Liability


    Ketamine Preservative Benzethonium Chloride Potentiates Hippocampal Synaptic Transmission and Binds Neurotransmitter Receptors and Transporters


    Essential Role of P-Glycoprotein in the Mechanism of Action of Oliceridine


    The SARS-CoV-2 Spike Protein Binds and Modulates Estrogen Receptors


    A Tool for Monitoring Cell Type Specific Focused Ultrasound Neuromodulation and Control of Chronic Epilepsy​​


    6-O-(2-[18F]Fluoroethyl)-6-O-desmethyl-diprenorphine ([18F]FE-DPN) Preferentially Binds to Mu Opioid Receptors In Vivo


    Adolescent Nicotine Administration Increases Nicotinic Acetylcholine Receptor Binding and Functional Connectivity in Specific Cortico-Striatal-Thalamic Circuits


    Target Deconvolution Studies of (2R,6R)-Hydroxynorketamine: An Elusive Search


    The Show Must Go On. Reply to “Distinct functions of S-ketamine and R-ketamine in mediating biobehavioral processes of drug dependency: comments on Bonaventura et al” by Insop Shim


    Time Will Tell. Reply to “Comments to pharmacological and behavioral divergence of ketamine enantiomers by Jordi Bonaventura et al.” by Chen et al


    Mechanisms of Ketamine and its Metabolites as Antidepressants



    Chemogenetics as a Neuromodulatory Approach to Treating Neuropsychiatric Diseases and Disorders


    Synaptic Zinc Potentiates the Effects of Cocaine on Dopamine Neurotransmission and Behavior


    Evidence in Primates Supporting the Use of Chemogenetics for the Treatment of Human Refractory Neuropsychiatric Disorders


    Pharmacological and Behavioral Divergence of Ketamine Enantiomers: Implications for Abuse Liability


    Translational PET Imaging Applications for Brain Circuit Mapping and Manipulation with Transgenic Tools


    18F-labeled Radiotracers for In Vivo Imaging of DREADDs with Positron Emission Tomography



    DREADD Approach to Treatment of Sleep Disordered Breathing​



    High-potency Ligands for DREADD Imaging and Activation in Rodents and Monkeys​


    The Neuroscience of Drug Reward and Addiction




    Ultrapotent Chemogenetics for Research and Potential Clinical Applications



    Ultrastructural Localization of DREADDs in Monkeys




    Opioid-Galanin Receptor Heteromers Mediate the Dopaminergic Effects of Opioids​


    Nucleus Accumbens Drd1-Expressing Neurons Control Aggression Self-Administration and Aggression Seeking in Mice


    Motivational Valence is Determined by Striatal Melanocortin 4 Receptors​




    Striatal Rgs4 Regulates Feeding and Susceptibility to Diet-induced Obesity​




    Chemogenetics Revealed: DREADD Occupancy and Activation via Converted Clozapine



    Dopamine D2 Receptor Signaling in the Nucleus Accumbens Comprises a Metabolic-Cognitive Brain Interface Regulating Metabolic Components of Glucose Reinforcement​


    Acute Engagement of Gq-mediated Signaling in the Bed Nucleus of the Stria Terminalis Induces Anxiety-like Behavior




    Elucidation of The Behavioral Program and Neuronal Network Encoded by Dorsal Raphe Serotonergic Neurons





    DREAMM: A Biobehavioral Imaging Methodology for Dynamic in vivo Whole-brain Mapping of Cell Type-specific Functional Networks




    Whole-brain Circuit Dissection in Free-moving Animals Reveals Cell-specific Mesocorticolimbic Networks


    Impaired Periamygdaloid-Cortex Prodynorphin is Characteristic of Opiate Addiction and Depression


    Limbic Activation to Novel Versus Familiar Food Cues Predicts Food Preference and Alcohol Intake


    PET Imaging Predicts Future Body Weight and Cocaine Preference​



    Dopamine-related Frontostriatal Abnormalities in Obesity and Binge-eating Disorder: Emerging Evidence for Developmental Psychopathology​


    Translational Neuroimaging in Drug Addiction and Obesity






    Dopamine D4 Receptors Modulate Brain Metabolic Activity in the Prefrontal Cortex and Cerebellum at Rest and in Response to Methylphenidate​


  • Tools & Resources

    Chemogenetics & Optogenetics

    Radioligands & Imaging Agents

    Our lab has pioneered the use of the agents below for non-invasive localization of chemogenetic and optogenetic switches in various species with the ultimate goal being human application.


    [3H]ASEM - In vitro PSAM4-GlyR & PSAM4-5HT3 quantification

    [18F]ASEM - Longitudinal In vivo PSAM4-GlyR & PSAM4-5HT3 quantification


    [3H]Clozapine - In vitro hM3Dq/hM4Di quantification

    [3H]Compound 13 (C13) - In vitro hM3Dq/hM4Di quantification

    [18F]JHU37107 (J07) - Longitudinal In vivo hM3Dq/hM4Di quantification


    [18F]fluoroestradiol (FES) - Longitudinal In vivo Opsin quantification (coming soon)



    Gomez, Bonaventura et al. 2017

    Magnus, Lee et al., 2019

    Bonaventura, Eldridge, Hu, et al., 2019

    Fleury Curado, et al., 2020

    Hu, Bonventura et al., 2020

    Chemogenetic agonists

    Our lab has developed the first DREADD agonists that exhibit high affinity, high in vivo potency, and high brain penetrance in several species, which favors clinical translation. These compounds require very low systemic doses (<0.1 mg/kg) to facilitate rapid and remote activation of chemogenetic switches in the brain.


    JHU37160 - hM3Dq/hM4Di agonist

    JHU37152 - hM3Dq/hM4Di agonist



    Bonaventura, Eldridge, Hu, et al., 2019


    For translational and clinical gene therapy applications, chemogenetic/optogenetic switches need to be optimized to drive efficient expression and trafficking to the cell membrane, where their respective actuators would achieve maximum efficacy. For this reason, our goal has been to optimize existing chemogenetic/optogenetic gene therapy constructs for optimal expression and targeting. One way of doing this is to strip bulky and potentially toxic fluorescent reporters, typically used in such designs, and which are not useful for translational and clinical applications. Our strategy is to leverage the use of our translational PET-based reporters for non-invasive and longitudinal quantification of chemogenetic/optogenetic switches along with small epitopes (e.g. HA-tag) whenever in vitro detection would be necessary.


  • Highlights

    The role of the estrogen receptor in COVID-19​

    Our recent work highlighted in the journal Nature Italy. Interview by first author Dr. Oscar Solis.

    December 12 2022

    Cooperative Research and Development Agreement (CRADA) with Attune Neurosciences, Inc.

    Mike Michaelides to serve as a co-PI on a CRADA with Attune Neurosciences, Inc. to develop focused ultrasound applications for neuromodulation

    December 22 2021

    Cooperative Research and Development Agreement (CRADA) with Redpin Therapeutics, Inc.

    Mike Michaelides to serve as a PI on a CRADA with Redpin Therapeutics, Inc. to develop chemogenetic applications for translational applications

    June 16 2021

    NIH Scientists Redesign Neurons to Enable Targeted Therapies

    Our recent work highlighted in the NIH I am Intramural Blog

    March 17 2021

    Interview on CODA Biotherapeutics at STAT+

    Mike's interview at STAT+

    February 5 2020

    Presentation at the Brain Initiative's "Chemogenetic Innovations in the Manipulation & Monitoring of Labeled Neurons Workshop"

    Mike presented at this NIH Brain Initiative Workshop

    December 10 2019

    Presentation at the ACNP 2019 Annual Meeting describing our optogenetics molecular imaging technology

    Mike presented at the ACNP 2019 "Hot Topics"

    December 10 2019

    "Changing the Locks" article and interview for Chemistry World about our work and that of others on chemogenetics.

    Mike's interview at Chemistry World

    May 20 2019

    Interview for Science magazine: Could deep brain stimulation help zap diabetes?

    Mike's interview for Science

    May 23 2018

    Interview for the American Psychiatric Association (APA): DREADDs Could Guide More Targeted Treatments in Future

    Mike's interview for Psychiatric News

    March 16 2018

    Research highlight about our recent work on chemogenetics

    Our recent work highlighted in the journal Nature Methods

    September 29 2017

    Research highlight about our recent work on chemogenetics

    Our recent work highlighted in the journal Nature Chemical Biology

    September 19 2017

  • Alumni

    Matthew Boehm, Ph.D.

    PhD Student, NIH GPP Program/Brown University


    Current -


    Meghan Carlton, B.S.

    IRTA Postbaccalaureate Fellow


    Current - PhD student

    Albert Einstein School of Medicine

    Jordi Bonaventura, Ph.D.

    Research Fellow


    IRTA Postdoctoral Fellow


    Current - Assistant Professor

    University of Barcelona

    Sherry Lam, B.S.

    Research Technician


    IRTA Postbaccalaureate Fellow


    Current - M.A. student

    Rutgers University

    Theresa Kopajtic, B.S.

    Research Biologist


    Current - Retired

    Kelsey Wright, B.S.

    IRTA Postbaccalaureate Fellow


    Current - Ph.D. Student

    Northwestern University

    Dondre Marable, B.S.

    IRTA Postbaccalaureate Fellow/Diversity Fellow


    Current - Entrepreneur/Industry

    Jatia Mills, B.S.

    RTURP Research Fellow

    Summer 2018

    Current - Ph.D. student

    Biomedical and Veterinary Sciences, Virginia Tech

    Weilin Chan, B.S.

    Special Volunteer/Summer Student


    Current - M.D. Student

    University of Buffalo

    Randall J. Ellis, B.S.

    IRTA Postbaccalaureate Fellow


    Current - Ph.D. student

    Biophysics & Systems Pharmacology

    Icahn School of Medicine at Mount Sinai

    Lionel A. Rodriguez, B.S.

    IRTA Postbaccalaureate Fellow


    Current - Ph.D. student,


    Johns Hopkins University

    Margaret Jokoh

    RTURP Research Fellow

    Summer 2016

    Current - Student, Loyola University

    Kat Daly, B.S.

    Lab rotation, NIH GPP program

    Spring 2016

    Current - Ph.D. student

    JHU/NIH GPP Program

  • Collaborators

    Marcello Allegretti, Ph.D.

    Dompé farmaceutici S.p.A

    Veronica A. Alvarez, Ph.D.

    National Institute on Alcohol Abuse & Alcoholism

    Yeka Aponte, Ph.D.

    National Institute on Drug Abuse

    Michael J. Bannon, Ph.D.

    Wayne State University

    Michael Baumann, PhD

    National Institute on Drug Abuse

    Miriam E. Bocarsly, Ph.D.

    Rutgers New Jersey Medical School

    Jordi Bonaventura, Ph.D.

    Universitat De Barcelona

    Charles W. Bradberry, Ph.D.

    National Institute on Drug Abuse

    Luis De Lecea, Ph.D.

    Stanford University

    Sergi Ferré, M.D., Ph.D.

    National Institute on Drug Abuse

    Adriana Galvan, Ph.D.

    Emory University/Yerkes

    Cameron Good, Ph.D.

    Attune Neurosciences, Inc. & NeuroLux, Inc.

    Todd D. Gould, M.D.

    University of Maryland Medical Center

    Brandon K. Harvey, Ph.D.

    National Institute on Drug Abuse

    Andrew G. Horti, Ph.D.

    Johns Hopkins University School of Medicine

    Robert B. Innis, M.D., Ph.D.

    National Institute of Mental Health

    Sanjay K. Jain, M.D.

    Johns Hopkins University School of Medicine

    Ned H. Kalin, M.D.

    University of Wisconsin Madison

    Lorenzo Leggio, M.D., Ph.D.

    National Institute on Drug Abuse

    Carl R. Lupica, Ph.D.

    National Institute on Drug Abuse

    Stephen V. Mahler, Ph.D.

    University of California at Irvine

    Ruin Moaddel, Ph.D.

    National Institute on Aging

    Marisela Morales, Ph.D.

    National Institute on Drug Abuse 

    Patrick J. Morris, Ph.D.

    National Center for Advancing Translational Sciences

    Sadegh Nabavi, Ph.D.

    Aarhus University

    Kendall W. Nettles, Ph.D.

    Scripps Research Institute

    Marco Pignatelli, M.D.

    Washington University School of Medicine in St. Louis

    Vsevolod Y. Polotsky, M.D., Ph.D.

    Johns Hopkins University School of Medicine

    Martin G. Pomper, M.D., Ph.D

    Johns Hopkins University School of Medicine

    Kenner C. Rice, Ph.D.

    National Institute on Drug Abuse

    Barry Richmond, M.D.

    National Institute of Mental Health

    Avi Z. Rosenberg, M.D., Ph.D.

    Johns Hopkins University School of Medicine

    Yavin Shaham, Ph.D.

    National Institute on Drug Abuse

    Lei Shi, Ph.D.

    National Institute on Drug Abuse

    David R. Sibley, Ph.D.

    National Institute on Neurological Disorders and Stroke

    Elliot A. Stein, Ph.D.

    National Institute on Drug Abuse

    Scott M. Sternson, Ph.D.

    University of California, San Diego

    Gianluigi Tanda, Ph.D.

    National Institute on Drug Abuse

    Craig J. Thomas, Ph.D.

    National Center for Advancing Translational Sciences

    Zheng-Xiong Xi, Ph.D.

    National Institute on Drug Abuse

    Menghang Xia, Ph.D.

    National Center for Advancing Translational Sciences

    Carlos A. Zarate Jr., M.D.

    National Institute of Mental Health

    Wei Zheng, Ph.D.

    National Center for Advancing Translational Sciences

  • Where to find us

    NIDA Intramural Research Program

    Biomedical Research Center

    251 Bayview Blvd

    Baltimore MD 21224

    tel: 1-443-740-2894

    fax: 1-443-740-2122